Neoadjuvant nivolumab and cabozantinib in advanced renal cell carcinoma in a horseshoe kidney - how to achieve a safe and radical resection? a case report and review of the literature

被引:1
作者
Zemankova, Anezka [1 ]
Studentova, Hana [1 ]
Kopova, Andrea [1 ]
Tichy, Tomas [2 ]
Student, Vladimir [3 ]
Melichar, Bohuslav [1 ]
机构
[1] Palacky Univ, Univ Hosp Olomouc, Fac Med & Dent, Dept Oncol, Olomouc, Czech Republic
[2] Palacky Univ, Univ Hosp Olomouc, Fac Med & Dent, Dept Clin & Mol Pathol, Olomouc, Czech Republic
[3] Palacky Univ, Univ Hosp Olomouc, Fac Med & Dent, Dept Urol, Olomouc, Czech Republic
关键词
renal carcinoma; neoadjuvant; immunotherapy; cabozantinib; nivolumab; complete response; horseshoe kidney; case report; THERAPY; SUNITINIB; NEPHRECTOMY; MANAGEMENT;
D O I
10.3389/fonc.2023.1115901
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionNeoadjuvant nivolumab and cabozantinib in locally advanced renal cell carcinoma in a horseshoe kidney is a novel therapeutic approach in the preoperative setting. MethodsWe report a case of a 52-year old male who presented with a large inoperable tumor of the horseshoe kidney and achieved major partial radiologic response after neoadjuvant therapy with nivolumab and cabozantinib leading to radical resection of the tumor. The patient remains tumor free on the subsequent follow-up and his renal function is only mildly decreased. The systemic treatment was complicated by hepatotoxicity leading to early nivolumab withdrawal. ResultsCurrently, the combination therapy based on immune checkpoint inhibitors and tyrosine kinase inhibitors represents the treatment of choice in treatment-naive patients with metastatic renal cell carcinoma in any prognostic group. The neoadjuvant treatment approach is being tested in prospective clinical trials and results are eagerly awaited. Renal cell carcinoma in a horseshoe kidney is an uncommon finding that is always challenging. Additionally, management guidance in this patient population is lacking. In some patients neoadjuvant therapy could be the only way to preserve kidney function. The initial treatment strategy should be individualized to patient needs aiming at the radical resection of the primary tumor as the only chance of getting the tumor under control in the long term. ConclusionHerein, we highlight the feasibility of neoadjuvant systemic therapy with nivolumab and cabozantinib allowing the subsequent performance of radical tumor resection with negative margins in a patient with advanced renal cell carcinoma in a horseshoe kidney, removing the primary tumor while sparing the patient from lifelong dialysis.
引用
收藏
页数:6
相关论文
共 25 条
[1]   Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial [J].
Allaf, M. ;
Kim, S. E. ;
Harshman, L. C. ;
McDermott, D. F. ;
Master, V. A. ;
Signoretti, S. ;
Cole, S. ;
Moon, H. ;
Adra, N. ;
Singer, E. A. ;
Gills, J. ;
Choueiri, T. K. ;
Leibovich, B. ;
Michaelson, M. D. ;
Shuch, B. ;
Lara, P. N. ;
Heng, D. Y. C. ;
Kapoor, A. ;
Carducci, M. A. ;
Haas, N. B. .
ANNALS OF ONCOLOGY, 2022, 33 (07) :S1432-S1433
[2]   Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful? [J].
Bigot, Pierre ;
Fardoun, Tarek ;
Bernhard, Jean Christophe ;
Xylinas, Evanguelos ;
Berger, Julien ;
Roupret, Morgan ;
Beauval, Jean-Baptiste ;
Lagabrielle, Samuel ;
Lebdai, Souhil ;
Ammi, Myriam ;
Baumert, Herve ;
Escudier, Bernard ;
Grenier, Nicolas ;
Hetet, Jean-Francois ;
Long, Jean-Alexandre ;
Paparel, Philippe ;
Rioux-Leclercq, Nathalie ;
Soulie, Michel ;
Azzouzi, Abdel-Rahmene ;
Bensalah, Karim ;
Patard, Jean-Jacques .
WORLD JOURNAL OF UROLOGY, 2014, 32 (01) :109-114
[3]   Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report [J].
Bilen, Mehmet A. ;
Jiang, James F. ;
Jansen, Caroline S. ;
Brown, Jacqueline T. ;
Harik, Lara R. ;
Sekhar, Aarti ;
Kissick, Haydn ;
Maithel, Shishir K. ;
Kucuk, Omer ;
Carthon, Bradley ;
Master, Viraj A. .
FRONTIERS IN ONCOLOGY, 2021, 10
[4]   Neoadjuvant therapy for localized and locally advanced renal cell carcinoma [J].
Bindayi, Ahmet ;
Hamilton, Zachary A. ;
McDonald, Michelle L. ;
Yim, Kendrick ;
Millard, Frederick ;
McKay, Rana R. ;
Campbell, Steven C. ;
Rini, Brian I. ;
Derweesh, Ithaar H. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (01) :31-37
[5]   The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma [J].
Borregales, Leonardo D. ;
Adibi, Mehrad ;
Thomas, Arun Z. ;
Wood, Christopher G. ;
Karam, Jose A. .
THERAPEUTIC ADVANCES IN UROLOGY, 2016, 8 (02) :130-141
[6]   Safety of Presurgical Targeted Therapy in the Setting of Metastatic Renal Cell Carcinoma [J].
Chapin, Brian F. ;
Delacroix, Scott E., Jr. ;
Culp, Stephen H. ;
Gonzalez, Graciela M. Nogueras ;
Tannir, Nizar M. ;
Jonasch, Eric ;
Tamboli, Pheroz ;
Wood, Christopher G. .
EUROPEAN UROLOGY, 2011, 60 (05) :964-971
[7]   Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].
Choueiri, T. K. ;
Powles, T. ;
Burotto, M. ;
Escudier, B. ;
Bourlon, M. T. ;
Zurawski, B. ;
Juarez, V. M. Oyervides ;
Hsieh, J. J. ;
Basso, U. ;
Shah, A. Y. ;
Suarez, C. ;
Hamzaj, A. ;
Goh, J. C. ;
Barrios, C. ;
Richardet, M. ;
Porta, C. ;
Kowalyszyn, R. ;
Feregrino, J. P. ;
Zolnierek, J. ;
Pook, D. ;
Kessler, E. R. ;
Tomita, Y. ;
Mizuno, R. ;
Bedke, J. ;
Zhang, J. ;
Maurer, M. A. ;
Simsek, B. ;
Ejzykowicz, F. ;
Schwab, G. M. ;
Apolo, A. B. ;
Motzer, R. J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) :829-841
[8]   Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) [J].
Cottrell, T. R. ;
Thompson, E. D. ;
Forde, P. M. ;
Stein, J. E. ;
Duffield, A. S. ;
Anagnostou, V. ;
Rekhtman, N. ;
Anders, R. A. ;
Cuda, J. D. ;
Illei, P. B. ;
Gabrielson, E. ;
Askin, F. B. ;
Niknafs, N. ;
Smith, K. N. ;
Velez, M. J. ;
Sauters, J. L. ;
Isbell, J. M. ;
Jones, D. R. ;
Battafarano, R. J. ;
Yang, S. C. ;
Danilova, L. ;
Wolchok, J. D. ;
Topalian, S. L. ;
Velculescu, V. E. ;
Pardoll, D. M. ;
Brahmer, J. R. ;
Hellmann, M. D. ;
Chaft, J. E. ;
Cimino-Mathews, A. ;
Taube, J. M. .
ANNALS OF ONCOLOGY, 2018, 29 (08) :1853-1860
[9]  
de Velasco Guillermo, 2020, Oncotarget, V11, P4457, DOI 10.18632/oncotarget.27807
[10]   Current Status of Immunotherapy for Localized and Locally Advanced Renal Cell Carcinoma [J].
Ghali, Fady ;
Patel, Sunil H. ;
Derweesh, Ithaar H. .
JOURNAL OF ONCOLOGY, 2019, 2019